Background {#Sec1}
==========

Breast cancer is the most commonly occurring female cancer in developed countries. Over 40,000 breast cancer deaths and approximately 250,000 new cases were reported in 2016 \[[@CR1]\]. The survival rate in HER2+ breast cancer patients \[[@CR2]\] has been remarkably increased through targeted therapies including tyrosine kinase inhibitors. Adjuvant treatments such as chemotherapy also improved the 5-year survival rate of the breast patients \[[@CR3], [@CR4]\]. However, the significant side effects of chemotherapy can shorten the lifespan of cancer patients in some cases \[[@CR5]\]. Additionally, due to potential metastasis and invasion of cancer, the overall outcome for breast cancer patients remains bleak. An effective survival predictor, which is capable of helping cancer treatment and foreseeing the clinical outcomes, can improve life quality and lifespan of cancer patients. Thus, better prognostic biomarkers of survival risk prediction are needed.

In clinical practice, clinicopathological prognostic indicators, such as tumor size, lymph node (LN) status and pathological grade \[[@CR6], [@CR7]\] have been widely used in prognostic analysis models. However, in some cases, the treatment responses vary greatly even with similar prognoses. Recently, single cell genomics analysis have shown that ostensibly similar tumor defined by traditional pathological analysis could be distinct diseases at the cell levels \[[@CR8]--[@CR10]\]. Due to the highly heterogeneous nature of cancer cells, the predictive ability of some traditional indicators can be less effective for over 50% of patients \[[@CR11]\].

Multiple survival analysis models have developed mainly based on gene expression profiles. The cox regression model and machine learning algorithms have been widely used to reveal molecular signatures related to survival. Bair et al. \[[@CR12]\] used semi-supervised methods to cluster patients with different survival risk based on gene expression profiles and clinical data. Sun et al. \[[@CR13]\] applied univariate Cox regression analysis and identified nine long noncoding RNAs (lncRNAs) that were highly associated with their metastasis-free survival for breast cancer patients. Zhang et al. \[[@CR14]\] developed a two-stage method, using Bayesian hierarchical Cox model and the penalized Cox model, and incorporated pathway information with gene expression profiles to predict survival.

Most survival prediction methods mainly utilize gene expression profiles. Somatic mutations are involved in the cancer development \[[@CR15]\]. Several studies showed that genetic mutations are associated with cancer survival, such as BRCA1- and BRCA2-related mutations, and HER2 somatic mutations \[[@CR16], [@CR17]\]. Thus, identifying survival related mutations are meaningful for prognosis and treatment. However, it is difficult to detect mutation patterns in a patient cohort for survival analysis since most commonly mutated genes are found in less than 10% of patients. Consequently, using common mutations alone to predict survival is less effective. To address this issue, we integrated somatic mutations with pathway, function annotation and gene ontology (GO) analysis. We then synergistically used the significantly mutated gene sets as predictors coupled with gene expression for survival analysis. Our results suggested that combining somatic mutations improved the performance of survival risk prediction.

Results {#Sec2}
=======

Gene differential expression and survival risk detection {#Sec3}
--------------------------------------------------------

We identified 4327 differentially expressed genes (adjust P-value \< 0.01 and \|logFC\| \> 2) based on the gene expression profile for 1091 breast cancer patients (151 deceased and 940 living) and 113 normal tissue samples, using the software tools developed in our laboratory (<http://mqyang.net>) along with other existing tools. Next, we applied univariate cox regression analysis to select the differential expressed genes that were also associated with survival. Out of 4327 genes, 330 were significantly associated with survival time (P-value \<  0.05). The patients were clustered into two distinct groups, high survival risk and low survival risk, using k-means according to the expression levels of 330 survival-related genes. Then, a Cox proportional hazards model was fitted to the patient survival data for the two groups (Fig. [1a](#Fig1){ref-type="fig"}). We calculated the Concordance index (C-index) to assess the predictive ability of our survival model. The C-index measures the concordance between the observed survival times and predicted survival times. The C-index of 330 gene signature-based model was 0.584 (P-value = 0.0011).Fig. 1The survival analysis using different type of features. The Kaplan--Meier curves for 330 significant univariate genes (**a**), 118 significant univariate genes with hazard ratios higher than 1.221(**b**), 88 genes that select by GA (**c**). **d** showed the C-index for these three models

Out of the 330 genes, we further selected 118 genes with hazard ratio \> 1.221. The resulting new prediction model yielded a higher C-index, 0.636.(P-value \< 0.001). According to Kaplan--Meier curve (Fig. [1b](#Fig1){ref-type="fig"}), the survival rate of 1500 days (4 years and 1 month) was 63.2% and 12.5% for patients in the low risk group and high risk group, respectively (Fig. [1b](#Fig1){ref-type="fig"}). The 118 genes contained several well-known breast cancer survival related genes or oncogenes, including *FOXR2, FOXD1, MTNR1B* and *SDC1* \[[@CR18]--[@CR24]\]. Additionally, PANTHER \[[@CR25]\] pathway analysis revealed 17 biological processes that were significantly enriched in the 118 genes (Additional file [1](#MOESM1){ref-type="media"}). Some are known biological process related to cancer, such as: DNA replication (P-value = 0.037), structural molecule activity (P-value = 0.00035), system development (P-value =0.00047), and cytoskeleton (P-value 0.000062) \[[@CR26]--[@CR28]\], while some others have not  been well studied (Additional file [1](#MOESM1){ref-type="media"}), such as peptide cross-linking (P-value=0.00027).

Survival-related genes selected by genetic algorithm {#Sec4}
----------------------------------------------------

We developed a genetic algorithm (GA)-based method to further optimize gene selection from original 330 significant univariate genes. The method is able to assess the combinatorial effects of multiple genes on survival. As a result, 88 genes were revealed as the optimal gene set which maximized the C-index. Using this gene set, we conducted survival analysis (Fig. [1c](#Fig1){ref-type="fig"}) and achieved a better c-index 0.656 compared to 0.636 yielded by the model constructed based on the 118 genes selected by hazard ratio. We found that 67 of 88 (75.3%) genes were overlapped with the 118-gene set. Hence, hazard ratio from the univariate test may not be the only factor that determines the prediction accuracy. Nevertheless, genes with higher hazard ratio tend to have higher possibility to generate more accurate survival prediction. (Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2The hazard ratio values and the Kaplan--Meier estimator for an independent patient dataset. **a** The hazard ratios of 330 significant univariate genes (yellow) and 88 genes (blue) selected by GA. **b** The Kaplan--Meier curve using 61 of 88 GA selected genes for a METABRIC breast cancer patient dataset

We obtained an independent data set from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) \[[@CR29]\] to validate our models. This dataset includes the expression profile and clinical data for 2509 breast cancer tissue samples. We found 61 genes in the 88-gene set and 64 genes in the 118-gene set shown in the expression profile of this patient cohort. Similar data normalization and survival analysis were performed. The models based on both gene sets were able to separate the high-risk and low-risk survival groups (*P*-value \< 0.0001, Fig. [2b](#Fig2){ref-type="fig"} and Additional file [2](#MOESM2){ref-type="media"}). The C-index was 0.614 and 0.6004 for the models based on 61 GA-selected genes and 64 hazard-ratio-selected genes, respectively. Consistent with the result for the TCGA dataset, the gene set that was identified by GA searching yielded higher prediction accuracy.

Survival-related somatic mutations {#Sec5}
----------------------------------

A total of 105,425 single-nucleotide variances (SNVs) were identified in 1044 breast cancer patient samples (1044 of 1091 patients have mutation data). The maximum and median SNV mutation rate was 10.4% and 0.095%, respectively (Fig. [3a](#Fig3){ref-type="fig"}), while the maximum and median gene mutation rate was 32.95% and 0.48%, respectively. rs121913279 was the most frequent SNP, which was located at the *PIK3CA* gene. *TP53*, *PIK3CA*, *TTN*, *CDH1*, *GATA3*, *MUC16*, *KMT2C* and *MAP3K1* were the top frequently mutated genes (Fig. [3a](#Fig3){ref-type="fig"}). The gene pairs consisting of these eight genes have differential mutation patterns, four pairs tend to mutual exclusively, while six pairs tend to be co-occurred (P-adjust \<= 0.008) (Table [1](#Tab1){ref-type="table"}). The C-index and *P*-value of the survival model based on these eight top mutated genes were 0.539 and 0.085. We expanded the mutated gene list to 88, 118, 330, which matched the number of differential genes used in the survival models. The resulting c-index for these different gene signature set was 0.565, 0.522 and 0.567, and corresponding P-value was 0.035, 0.23 and 0.028. Thus, the top mutated genes were not necessarily effective gene signatures for survival prediction; the correlation coefficient of gene mutation rates and P-values of the univariate tests was − 0.22 (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3Distribution of mutation rates and the correlation with univariate P-values. **a** The distribution of mutation rates for genes and SNPs in the TCGA breast cancer patients. **b** The correlation between univariate *P*-value and mutation rate for top 35 mutated genesTable 1The top mutated genes in the TCGA 1044 breast cancer datasetGene AGene BA Not BB Not ABothLog Odds RatioAdjusted *p*-ValueTendency*TP53CDH1*3381259−2.067\<  0.001Mutual exclusivity*TP53GATA3*33611611−1.771\<  0.001Mutual exclusivity*TP53MAP3K1*3367911−1.327\<  0.001Mutual exclusivity*TP53PIK3CA*26526682−0.641\<  0.001Mutual exclusivity*PIK3CACDH1*28470640.7350.002Co-occurrence*TP53TTN*264104830.620.004Co-occurrence*PIK3CAKMT2C*29655520.750.006Co-occurrence*TTNKMT2C*15474330.8460.007Co-occurrence*PIK3CAMAP3K1*30345450.7980.008Co-occurrence*TTNMUC16*14668411.209\<  0.001Co-occurrence

To combine gene expression and mutation for survival analysis, we first clustered the breast cancer patients into two groups (high survival risk and low survival risk) based on the expression levels of 118 genes. Then we analyzed the corresponding somatic mutation profiles for the patients in the distinct groups. We found that 48,404 and 57,024 SNVs were found for the patients in the high-risk group and the low risk group, respectively.

We compared the percentage of different types of SNVs in the two groups (Fig. [4a](#Fig4){ref-type="fig"}). The C- \> G and G- \> C SNVs frequencies in the high-risk group were significantly higher than these SNVs (13.1% versus 8.31%, 12.6% versus 7.82%) in the low risk group (t-test, P-value = 5.5e-14, P-value = 1.3e-14). We thus used C- \> G and G- \> C SNP frequencies as the two features to perform survival analysis. The survival risk curves showed a noticeable yet insignificant difference ( P-value= 0.36). Combining the 118 gene expression with C- \> G and G- \> C SNP frequencies, we conduct another survival analysis. We obtained similar prediction accuracy as using the gene expression alone (Fig. [4b](#Fig4){ref-type="fig"}). Our results suggested that GC SNV frequencies were weaker features for survival prediction.Fig. 4The mutation of different SNP types. **a** The frequencies of different SNP types in the high and low risk groups. **b** The Kaplan--Meier curve for using C → G and G → C SNP frequency combine with 118 gene expression as indicators

We also calculated the mutation rates of all genes in the high-risk and low-risk groups. The mutation rate here refers to the percentage of the patients who harbored somatic mutation(s) in a specific gene in the patient group. Then we computed the mutation rate differential scores (MRDS)(Method) for each individual genes.

Some genes showed quite distinct mutation rates in the different groups. For example, the mutation rates of *TP53* in the high and low risk group were 0.634 and 0.208, respectively. We selected the top 2000 genes ranked by MRDS. Multiples genes in this list present in breast cancer related pathways. For example, *ATM, ATR, TP53, PTEN, CASP8, and IGFBP3* participate in p53 signal pathway, while *MMP, EGFR, CREP, PLC, and RAS* participate in estrogen signaling pathway.

Based on DAVID analysis \[[@CR30], [@CR31]\], we identified 30 pathways, 114 functional annotations and 38 Gene Ontology (GO) terms that were significantly enriched of the 2000 mutated genes (*P*-value \< 0.05). We then build new features using these molecular function gene sets. If a patient carried mutation(s) in at least one gene of individual enriched function gene sets, we set the corresponding feature value as 1; otherwise we set the value as 0. Then we performed a univariate Cox regression analysis for each of new features. As a result, we identified 15 function annotations (FA), 15 GO terms and 14 pathways that were significant in the univariate test (*P*-value \< 0.05 and hazard ratio \> 1.221). Using a total of 54 mutated functional gene set, the C-index survival model was 0.591 (P-value = 0.0016). The C-index of the models that utilized different type of gene set (Table [2](#Tab2){ref-type="table"}) showed that integrating gene expression and mutation analysis generated a survival model with better accuracy (Table [2](#Tab2){ref-type="table"}) (Fig. [4b](#Fig4){ref-type="fig"}).Table 2C-index of the Cox proportional hazards models based on different featuresFeature typeFeaturesC-index*P*-valueGene expression330 significant univariate genes0.5840.0011118 significant univariate genes with hazard ratio \> 1.2210.636\<  0.000188 significant univariate genes selected by GA0.656\<  0.0001Somatic mutation25 functional annotations0.6030.001215 gene ontology terms0.5670.001314 pathways0.5480.003754 functional gene sets combining functional annotations, GO terms and pathways0.5910.0016Gene expression & somatic mutationAll 142 features (88 significant univariate genes and 54 functional gene sets)0.658\<  0.0001

Discussion {#Sec6}
==========

The gene signatures derived from expression profiles have commonly been used in survival analysis \[[@CR18]--[@CR21], [@CR24]\]. The survival-related genes are often selected through the univariate regression model. The resulting P-value and/or hazard ratio were used as criteria for gene selection. However, the gene list composed of the gene selected from the univariate tests may not be necessary the optimal gene set for the survival prediction. To address this limitation, we employed a GA searching algorithm to optimize gene set selection for accurate survival prediction. The GA searching enables the assessment of the combinatorial effect of a gene set on the survival analysis. As expected, we identified a set of genes that yielded higher prediction accuracy than the gene list obtained from the univariate regression model. In this study, the GA only searched for the best gene combination of 330 univariate genes, which was the length of initial chromosome. The pre-filtered gene candidate set can reduce the searching space of the GA algorithm and save the computation time, however, the optimal gene set could be overlooked by this strategy.

The cancer survival analysis merely using the gene expression levels shows the limited ability for accurate survival risk prediction \[[@CR32]\]. The genetic mutations have an important role in cancer development. Hence, the genetic mutation profiles can provide additional values for survival analysis and lead to uncover genetic variations that are associated with patient survival \[[@CR27]\]. We found that the most frequently mutated genes were not necessarily significant in survival analysis. The correlation coefficient of the top eight mutated genes and the *P*-values from the univariate regression model is − 0.22 in the breast cancer dataset that we studied. The mutated genes selected by the univariate regression test often resulted in very unbalanced survival risked groups (Additional file [3](#MOESM3){ref-type="media"}). In addition, it is commonly known that the drive gene mutations in a pathway tend to be mutually exclusive. Here, we proposed a system biology method: first projected the somatic mutations onto the pathways and gene function sets, then used significantly mutated pathways or function gene sets as additional signatures for survival analysis. For example, we found 14 pathways were significant abundance of the mutated genes as well as showed significance in the univariate regression test (Fig. [5](#Fig5){ref-type="fig"}). The mutated rates of these pathway-genes were relatively low (Additional file [4](#MOESM4){ref-type="media"}).Fig. 5The 14 pathways enriched by differential mutated genes. The 14 pathways were significantly enriched by the top 2000 differentially mutated genes with higher MRDS (blue bar). These pathways also showed significance in the Cox univariate regression test (yellow bar)

Despite of low mutation rate of pathway-gene, they tended to be more effective for survival prediction. In the Cox univariate regression, the 14 pathways consistently demonstrated lower *P*-values than the top mutated genes set (Additional file [5](#MOESM5){ref-type="media"}). Here, the number of top mutated genes set is the same as the number of mutated genes in the corresponding pathways. We also performed multivariate regression test. In the multivariate test, each individual mutated gene in the pathways or the top mutated genes was considered a feature. We found most pathway-genes tend to have high P-value than the individual top mutated genes, excepting the Fanconi anemia pathway and ECM-receptor interaction pathways. Specially, the Fanconi anemia pathway performed well in both univariate regression and multivariate regression models (Additional file [5](#MOESM5){ref-type="media"}), suggest this pathway has an essential role in the breast cancer survival.

In this study, we integrated somatic mutations with gene expression in our survival analysis and built an improved model for survival risk prediction. Further improvement could be achieved when several related issues are solved. First, previous studies showed that somatic mutation identification remains inaccurate \[[@CR33], [@CR34]\]. The mutations identified by different mutation callers often have relatively low overlap. Better mutation caller can potentially improve survival prediction accuracy. Second, somatic mutations are highly heterogeneous among patients. Identifying survival driver genes could be valuable for survival prediction. In addition, allele frequency, the mutation positions and the other mutation information can be further incorporated into the survival model for survival model enhancement. Unlike gene expression, the quantitative relationship between somatic mutation and phenotypic characteristics are unknown. With better understanding of somatic mutation roles in the patient survival, we can build a better prognosis model for survival analysis.

Conclusions {#Sec7}
===========

Our study suggested that expressions of genes were the effective indicators for breast cancer survival prediction. By coupling with somatic mutations, we were able to improve the survival predict model, however, the improvement was marginal. Also, we found that some genes demonstrated significantly distinct mutation rates between high risk and low risk breast cancer patients. Better utilizing the mutation difference for cancer prognostic analysis can be further investigated.

Methods {#Sec8}
=======

Breast cancer datasets {#Sec9}
----------------------

We obtained RNAseq datasets including raw counts and FPKM (Fragments Per Kilobase of transcript per Million) counts from TCGA (The Cancer Genome Atlas) project. The RNAseq datasets were generated from 1091 breast tumor tissue samples. We downloaded the somatic mutation profile generated by MuTect2 workflow, for 1044 tumor tissue samples. Out of 1044 cases in the somatic mutation file, 980 were common cases with gene expression profiles. Survival information was obtained from the metadata for each individual cases. All TCGA datasets used in the study are publicly available at the GDC Portal website (<https://portal.gdc.cancer.gov/>).

An independent breast cancer datasets including the patient clinical information and the expression profile for 2509 breast cancer patients were downloaded from *cBioportal* ([www.cbioportal.org](http://www.cbioportal.org)/). The data was generated by the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC).

An R-package 'edgeR' was applied for differential expression analysis. We used adjusted P-value lower than 0.01 and absolute log fold change larger than 2 to define significantly differentially expressed genes.

Feature selection {#Sec10}
-----------------

We first used the univariate Cox regression analysis to choose features for survival analysis. The output of the regression analysis includes three important statistics: statistical significance (p), regression coefficients (coef) (Eq. [1](#Equ1){ref-type=""}), and hazard ratios (HR) (Eq. [2](#Equ2){ref-type=""}). These statistics were used to select the significant survival-related features.$$\documentclass[12pt]{minimal}
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where x and y are two vectors that represent the survival time and one predictor variable. Base on C-index statistics, we chose the thresholds P-value  \<  0.05 and hazard ratios \> 1.221 for selecting survival-related genes.

Survival analysis {#Sec11}
-----------------

We normalized each feature gene-wisely using the following equation:$$\documentclass[12pt]{minimal}
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where *g*~*i*,\ *j*~ represent the value of feature i in the sample j. N is the total number patient samples and M is the total number of features. Then, we used k-means algorithm to identify high survival risk and low survival risk groups. Subsequently, each individual samples were labeled accordingly. Using R package "survival", the Cox proportional hazards model was fitted with the data and the corresponding C-index was calculated. The R package 'survminer' was used to plot the Kaplan--Meier curve.

Genetic algorithm identifies survival indicators {#Sec12}
------------------------------------------------

The genetic algorithm (GA) is a heuristic method for searching the global optimum. We employed the GA to reveal a gene set that yields the best survival prediction accuracy. An R package "Genalg" was used for GA searching. \[[@CR35]\]. We set the population size as 200. The chromosome is a 0/1 vector with the length of 330. Here, 330 is the total number of significant univariate genes, 1 means the corresponding gene is selected while 0 refer to the unselected gene. Mutate rate was set to 0.01. The fitness score was calculated by (1 - C-index) of each candidate gene set. The number of generation is set to 100.

Building somatic mutation and functional gene set based features {#Sec13}
----------------------------------------------------------------

Based on the gene signatures derived from the expression profiles, we divided the patients into high and low survival risk groups. Then, the somatic mutation profiles for patients in each group were extracted from the annotated somatic mutation file accordingly. For SNPs, we calculated and compared the percentage of various types of SNPs in the two groups. The t-test was applied to assess whether a type of SNPs demonstrated significantly different mutation rate between the two survival risk groups.

For mutated genes, we compared the mutation rate of each gene (i) in the two groups. Mutation rate (R) was calculated using the number of the samples containing the mutated gene divided by the total number of samples in the individual groups. Then, we calculated a mutation rate differential score (MRDS) for each gene (Eq. [4](#Equ4){ref-type=""}). The top 2000 genes with higher MRDS were selected for enrichment analysis.$$\documentclass[12pt]{minimal}
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The DAVID \[[@CR30], [@CR31]\] analysis was used to identify functional annotation sets, gene ontology terms and pathways that were enriched by the top differentially mutated genes.
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Additional file 1:PATHER significantly enriched terms base on 118 survival related genes. (DOCX 15 kb) Additional file 2:The Kaplan--Meier estimator for an independent patient dataset. The survival curve base on 64 of 118 hazard-ratio-selected genes for METABRIC breast cancer patient dataset. (PDF 119 kb) Additional file 3:The Kaplan--Meier estimator using top 35 mutated genes. The Kaplan--Meier curves using 35 mutated genes selected by the univariate regression as predictors displayed two very unbalanced survival risk groups. (PDF 15 kb) Additional file 4:The comparison of mutation rates for top mutated genes and 14 pathway genes. The mutation rates for 15 different gene sets, including one top-35-mutated gene set and 14 pathway-based gene sets. The genes in each set were ordered by their mutation rates. (PDF 36 kb) Additional file 5:The *P*-value of the Cox univariate regression analysis using different gene sets. (A) The *P*-values of the Cox univariate regression analysis for pathway-based genes (blue) and top mutated genes (orange). (B) The P-values of univariant test and multivariant test for pathway-based genes (blue and grey) and top mutated genes (orange and purple). (PDF 344 kb)

C-Index

:   Concordance Index

GA

:   Genetic Algorithm

GO

:   Gene ontology

LN

:   Lymph node

LOOCV

:   Leave-one-out cross-validated

METABRIC

:   Molecular Taxonomy of Breast Cancer International Consortium

SNPs

:   Single-Nucleotide Polymorphisms

TCGA

:   The Cancer Genome Atlas

TKIs

:   Tyrosine Kinase Inhibitors

This research was supported by United States National Institutes of Health (NIH) Academic Research Enhancement Award 1R15GM114739 and National Institute of General Medical Sciences (NIH/NIGMS) 5P20GM103429, and Arkansas Science and Technology Authority (ASTA) Basic Science Research 15-B-23 and 15-B-38. However, the information contained herein represents the position of the author(s) and not necessarily that of the NIH.

Funding {#FPar1}
=======

The publication cost of this article was funded by United States National Institutes of Health (NIH) Academic Research Enhancement Award 1R15GM114739.

Availability of data and materials {#FPar2}
==================================

The original data set used in this paper are publicly available on GDC data portal([https://portal.gdc.cancer.gov/](https://portal.gdc.cancer.gov/))) and cBioPortal([http://www.cbioportal.org/](http://www.cbioportal.org/))).

About this supplement {#FPar3}
=====================

This article has been published as part of *BMC Medical Genomics Volume 11 Supplement 5, 2018: Selected articles from the IEEE BIBM International Conference on Bioinformatics & Biomedicine (BIBM) 2017: medical genomics.* The full contents of the supplement are available online at <https://bmcmedgenomics.biomedcentral.com/articles/supplements/volume-11-supplement-5>.

MQY conceived the project. YZ and MQY designed the experiments. YZ performed the experiments and analysis. WY, DL, JY and RG participate in discussions. All authors have read and approved final manuscript.

Ethics approval and consent to participate {#FPar4}
==========================================

Not applicable.

Consent for publication {#FPar5}
=======================

Not applicable.

Competing interests {#FPar6}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
